Drug Profile
Bomedemstat - Imago BioSciences
Alternative Names: Bomedemstat tosylate - Imago BioSciences; IMG-241 bis-tosylate salt; IMG-7289; LSD1 inhibitor - Imago BioSciences; MK-3543Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Imago BioSciences
- Developer Imago BioSciences; University of Hong Kong
- Class Amides; Amines; Antihaemorrhagics; Antineoplastics; Benzamides; Benzene derivatives; Cyclopropanes; Fluorobenzenes; Piperazines; Small molecules; Triazoles
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential thrombocythaemia
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
- Phase I/II Small cell lung cancer
Most Recent Events
- 31 Dec 2023 Phase-III clinical trials in Essential thrombocythaemia (Treatment-experienced) in Israel (PO) (NCT06079879)
- 09 Dec 2023 Pharmacodynamics, efficacy and adverse events data from a phase II trial in Essential thrombocythaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Safety and efficacy data from a phase II trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)